8 results about "Bacteriophage Therapy" patented technology

The invention discloses a broad-spectrum lytic bacteriophage for preventing and controlling various vibrio infections in an aquaculture environment. The invention relates to V.alginolyticus phage vBValM-R37J, which is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on August 6, 2025, the address is No.100 Courtyard, Xianlie Middle Road, Xianlie District, Guangzhou City, Guangdong Province, the postcode is 510070, and the preservation number is GDMCC NO.66813-B1. The invention further discloses a method for preparing the V.alginolyticus phage vBValM-R37J strain. The bacteriophage R37J is a candidate therapeutic bacteriophage with wide host spectrum, high splitting efficiency, gene safety and environmental stability, and has the potential of being popularized and applied in aquaculture as a novel biological tool for accurately preventing and controlling various vibrio infections. A new biological resource is provided for accurate prevention and control of aquatic pathogenic bacteria, and a theoretical basis and a technical support are provided for popularization and application of a phage therapy in an actual culture system.

The present invention is directed to phage therapy for the treatment and control of bacterial infections, in particular urinary tract infections caused by Escherichia coli. More specifically, the present invention is directed to novel bacteriophage strains, cocktails thereof and variants thereof; and to methods using the same in the treatment, reduction or prevention of bacterial infections. The cocktail is used as a first line treatment against urinary tract infections, in particular in cancer patients, diabetic patients, or patients with a weakened immune system. Disclosed herein is a pharmaceutical composition comprising one or more purified strains of bacteriophage, each purified strain having a genome with at least 98% sequence identity to a nucleotide sequence selected from SEQ. ID No. 1, SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6 and / or variants thereof. The pharmaceutical composition may also be used in combination with other therapies for urinary tract infections such as antibiotics. The pharmaceutical composition may also be used in a method of diagnosis of the causative agent of a bacterial infection. A bacteriophage comprising at least 95% sequence identity with SEQ. ID No. 1, SEQ ID NO. 5 or SEQ ID NO. 6 is also disclosed.

This invention discloses a broad-spectrum Staphylococcus aureus bacteriophage, SapYZUbeta, and its applications. This bacteriophage has been deposited at the China Center for Type Culture Collection (CCTCC) on May 16, 2022, with accession number CCTCC NO: M 2022629. Identification revealed that the full-length gene of this bacteriophage is 17,790 bp, and it does not contain tRNAs or genes associated with lysogenicity, virulence, or antibiotic resistance. This genetic background confirms the safety of this bacteriophage for use against foodborne pathogens and for bacteriophage therapy. Furthermore, the bacteriophage exhibits a high titer of 1.9 × 10⁻⁶. 9 The phage, with a concentration of PFU / mL, exhibits stable activity within a pH range of 3–12 and a temperature range of -80–60°C, and can be applied to various matrices. The phage provided by this invention can lyse multidrug-resistant wild-type strains isolated from different regions, including MRSA and MSSA, and is characterized by a broad lysis spectrum and high lysis efficiency.

The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject.The subject invention also provides new bacteriophage strains.

The present invention relates to phage therapy. More specifically, the present invention relates to novel bacteriophages having high specificity for Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising them and their use in phage therapy.

Provided herein are therapeutic agents and compositions for treating infections associated with alcohol-associated hepatitis. Also provided herein are methods of expanding the host range of an Enterococcus faecalis, E. faecalis bacteriophage for the treatment of an alcohol-associated hepatitis associated infection.

The invention discloses a phage receptor binding protein host prediction method based on cross-modal multi-source transfer learning, which is characterized in that the host prediction precision is enhanced by utilizing chemical toxicity data, and the challenge of scarcity of phage sequence data is overcome. First, a shared bidirectional long short-term memory network encoder is used to process features from chemical and biological modalities, and structure and sequence information is captured. Next, domain adaptation is performed through a maximum mean difference loss function, effectively aligning chemical and biological feature representations. According to the method, knowledge migration of cross-modal data is realized, the accuracy of host prediction is remarkably improved, and particularly, the precision is improved by about 30% compared with that of a traditional model in the early stage of training. Experimental results show that the method provided by the invention can realize rapid convergence and is excellent in performance when being used for processing the problem of data scarcity, a novel efficient method is provided for host prediction in the field of biological medicines, especially in phage therapy, and the method has a wide application prospect.